mediaire
Series-A
Co-Investors: 2
Berlin, GER
Today radiologists are facing a dilemma: A skyrocketing number of medical images (CT and MR) but lack of sufficient radiologists/time to cope with this demand.
This triggers a chain of negative consequences – for everyone:
mediaire’s software (mdbrain, mdprostate) applies deep learning (AI) for highly efficient analyses of MR images (MRI) to support patients’ diagnosis, drastically improving the radiology workflow while reducing overall healthcare costs.
With their current product palette (mdbrain, mdprostate) mediaire can already cover about 9% of typical MRI Scans. With the additional products planned they will be able to increase this to 24% of all examinations.
The high quality of the mediaire software has already been confirmed by numerous customers and in 10+ publications in scientific journals.
The mediaire products like mdbrain, mdprostate and the planned Products mdknee and mdbrain+, are:
SaaS: Upfront installation fee and monthly fee.
Volume-based pricing starts at EUR 10 / report, decreasing EUR 1 / report.
mediaire’s customers are radiology clinics and hospitals equipped with modern MRI technology.
Estimated Market Size for MRI radiology market is EUR 44 billion in DACH, Italy, France and US alone. With its AI solutions in this space, there is a EUR 3 billion yearly market opportunity for mediaire with a potential to increase this to 5 billion worldwide.
Strong product-market fit and customer demand are proven by a negative net churn rate. This means that more turnover is earned with existing customers than is lost through churn.
The successful rollout of two body parts: Brain & Prostate – Knee is coming soon.
Monthly Revenue (MRR) tripled from Q1 2023 – Q1 2024
Successful entry in new markets such as Spain, Italy and Romania with big partners like Roche, Bayer etc.
CEO + Founder
CTO + Founder
CCO
CFO + COO
This document is non-binding preliminary information that provides an initial impression of the financing options offered. Neither this document nor the statements made by us in this context can be a sufficient basis for a financing decision. Investors should examine the possible investments themselves. Responsibility based on own analysis. This document does not constitute a sales prospectus, a public offer of an investment, an invitation to submit an offer, investment advice or investment brokerage. In providing this information, we make no representations, warranties or other contractual or quasi-contractual obligations, including with respect to the completeness, content or accuracy of the information reproduced in this document. This document is to be treated confidentially and may not be reproduced in whole or in part, passed on to third parties or published.
Bleiben Sie über die neusten Trends und Updates der Industrie mit unserem monatlichen Newsletter informiert.
© 2024 G8Way GmbH, Wien & München
The scenarios determined by the investment calculator are based on empirical values and assumptions. They are intended solely to illustrate possible developments and are no guarantee of future results. The actual performance of an investment may deviate significantly from the results forecast in the scenarios presented due to a wide range of macroeconomic and microeconomic factors. Start-up investments involve a high level of risk, which can extend to the total loss of the investment. It is expressly pointed out that neither Gateway Ventures nor its partners or representatives can be held liable for decisions made on the basis of the results of this calculator. Use of the calculator is at your own risk. You should seek independent financial advice and conduct your own research before making any investment decision.